Highest-materiality recent filing
Biodesix Q2 2026 revenue $26.9M (+34% YoY); net loss improves 37% to $7.3M
Diagnostic testing revenue $25.4M (+42% YoY) on 20,900 test volumes (+38%).
Biodesix shareholders elect directors, approve say-on-pay, ratify KPMG at 2026 annual meeting
Elected Jean Franchi (6.19M for, 0 against, 721.8K abstain) and Hany Massarany (6.85M for, 0 against, 66.2K abstain) as Class III directors until 2029.
Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M
Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).
Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M
Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.
Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4
Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.
Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M
Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).
Biodesix regains Nasdaq minimum bid price compliance; matter closed
Received Nasdaq letter on Sept. 26, 2025 confirming compliance regained.
Biodesix effects 1-for-20 reverse stock split, eliminates Series A preferred
Reverse stock split at 1:20 ratio effective Sep 15, 2025; new CUSIP 09075X207.
Biodesix announces 1-for-20 reverse stock split effective Sept 15, 2025
Reverse split ratio 1:20; shares outstanding drop from ~156M to ~8M.
Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M
Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).
Biodesix shareholders approve reverse stock split ratio range 1:2 to 1:20
Shareholders approved reverse stock split of common stock at ratio between 1-for-2 and 1-for-20, as determined by board.
Biodesix Q1 revenue $18M (+21% YoY); revises FY2025 guidance to $80-85M
Total Q1 2025 revenue $18.0M (+21% YoY); diagnostic testing $16.3M (+18%), development services $1.7M (+61%).
Two Biodesix directors resign effective May 20, 2025; Schuler named director emeritus
Charles Watts, M.D. resigns from Board and Compensation Committee effective at 2025 Annual Meeting (May 20, 2025).
Biodesix receives Nasdaq deficiency notice for bid price below $1.00 per share
Nasdaq notified Biodesix on March 24, 2025 that bid price closed below $1.00 for 30 consecutive business days.
Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M
FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.
Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint
Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.
Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY
Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).
Biodesix posts updated corporate presentation with no new financial or operational data
Presentation filed under Item 7.01 and available on IR website.
Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M
Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).
Biodesix shareholders elect three Class I directors and approve all proposals at 2024 annual meeting
Jon Faiz Kayyem, Scott Hutton, and John Patience elected as Class I directors with over 79M votes each.
Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M
Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).
Biodesix raises ~$51.6M in oversubscribed common offering and convertible preferred placement
Net proceeds ~$51.6M from 17.4M shares common at $1.15/share and 760,857 Series A Preferred at $46/share.
Biodesix Q4 revenue $14.7M (+53% YoY); guides FY2024 revenue $65-$68M
Full-year 2023 revenue $49.1M, +28% YoY; Lung Diagnostic test volume up 65%.
Biodesix draws $10M Tranche B loan from Perceptive; issues 1M-share warrants
Drew $10M Tranche B under existing $50M Perceptive term loan facility on Dec 15, 2023.
Biodesix Q3 2023: Lung diagnostic revenue up 34% YoY; net loss narrows 20%
Total revenue $13.5M (+21% YoY); lung diagnostics $12.3M (+34% YoY); Biopharma Services $1.2M (+79% YoY).
Biodesix Q2 core lung diagnostics revenue up 58% YoY to $11.4M; raises $27.5M
Core lung diagnostic revenue $11.4M (+58% YoY, +33% QoQ); gross margin 73% vs 64% in Q2 2022.
Biodesix completes stock option exchange; net reduction of ~600K shares
83 employees exchanged options; 757,595 shares cancelled (~99% of eligible).
Biodesix appoints Christopher Vazquez as CAO, replacing Ryan Siurek effective July 3, 2023
Ryan Siurek resigned as Chief Accounting Officer, effective July 3, 2023; no disagreement with company.
All three Class III director nominees (Jean Franchi, Hany Massarany, Jack Schuler) elected with >62M votes each.
Biodesix Q1 revenue $9.1M (+38% YoY); core lung diagnostics up 86% to $8.6M
Total revenue $9.1M, +38% YoY; core lung diagnostic revenue $8.6M, +86% YoY.
Biodesix Q4 core lung diag revenue $8.2M (+51% YoY); guides 2023 total rev $52-55M
Total revenue Q4 $9.6M, FY2022 $38.2M; core lung diagnostic revenue $29.3M (+57% YoY).
Biodesix appoints Lawrence T. Kennedy to Board of Directors, effective Jan 3, 2023
Kennedy appointed to Board and Audit Committee, effective Jan 3, 2023.
Biodesix raises $70.7M via $50M term loan and $40.3M equity; retires $24M in debt
Entered $50M Perceptive term loan; $30M drawn at close, two $10M tranches available on revenue milestones.
Biodesix Q3 core lung diagnostic revenue up 102% to $9.2M; guidance at high end
Core lung diagnostic revenue $9.2M (+102% YoY); total revenue $11.1M (+70% YoY).
Biodesix preliminary Q3 revenue $10.6M-$11.2M, core lung diagnostics up 96-103% YoY
Total Q3 2022 revenue estimated $10.6M-$11.2M, up 62-71% YoY.
Biodesix Q2 core lung diag revenue $7.3M (+52% YoY); net loss $15.8M; reaffirms 2022 guidance
Core lung diagnostic revenue $7.3M, up 52% YoY; total revenue $11.0M down 8% due to COVID test decline.
Biodesix stockholders elect two Class II directors and ratify KPMG as auditor
Matthew Strobeck, Ph.D. and Charles Watts, M.D. elected as Class II directors (23.1M votes for each).
Biodesix Q1 core lung diag rev $4.6M (+17% YoY); net loss $15.6M; raised $27.4M post-quarter
Core lung diagnostic revenue $4.6M (+17% YoY); total revenue $6.5M (-77% YoY) as COVID-19 testing fell 96%.
Biodesix raises $11.7M via private placement; amends 2021 term loan with SVB
Sold 6,508,376 shares at $1.79/share to consortium including board members, raising ~$11.7M.
Biodesix reports FY2021 revenue $54.5M; core lung diagnostic up 49% YoY to $18.7M; net loss $43.2M
Q4 total revenue $7.2M; core lung diagnostic revenue $5.4M (+48% YoY); BioPharma services $1.4M (-29% YoY).
Biodesix enters $50M common stock purchase agreement with Lincoln Park Capital
Up to $50M of common stock may be sold to Lincoln Park over 36 months at Biodesix's discretion.
Biodesix reports preliminary Q4 2021 revenue of $7.2M; core lung testing grows 49% YoY
Preliminary full-year 2021 total revenue of $54.5M, up from $45.6M in 2020.
Biodesix reports record full-year 2021 revenue of $54.5M; core lung diagnostic testing up 49%
Full-year 2021 total revenue $54.5M vs $45.6M in 2020; Q4 revenue $7.2M.
Biodesix raises ~$16.3M via ATM equity sale, repays $20M of term loan with SVB
Raised ~$16.3M from sale of 3,756,994 common shares in ATM offering on Dec 30, 2021.
Biodesix appoints Dr. Jon Faiz Kayyem to board of directors effective December 6, 2021
Dr. Kayyem brings 20+ years experience in molecular diagnostics, having founded GenMark Diagnostics and Clinical Micro Sensors.
Biodesix Q3 lung diagnostic revenue up 51% YoY; launches 72-hour NGS test
Total revenue $6.5M; lung diagnostic revenue $4.5M (+51% YoY), services $1.5M (+133%), COVID-19 testing $0.5M (-91%).
Biodesix posts corporate presentation; no material new information disclosed
Corporate presentation posted on investor relations website dated September 9, 2021.
Total revenue $11.9M (+180% YoY); core lung diagnostic revenue $4.8M (+109%).
On April 15, 2025, Charles Watts, M.D., a member of the Board of Directors (the “Board”) of Biodesix, Inc. (the “Company”), notified the Company of his intention to resign from his position as a director of the Board and as a member of the Compensation Committee, effective at the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 20, 2025.
On May 31, 2023, Ryan Siurek informed Biodesix, Inc. (“the Company”) of his resignation as Chief Accounting Officer, effective July 3, 2023.
Also effective July 3, 2023, the Company appointed Christopher Vazquez to serve as Chief Accounting Officer.
On December 15, 2022, Lawrence (Lair) T. Kennedy was elected and appointed to the Board of Directors of Biodesix, Inc. (the “Company”), with such appointment to be effective and service to commence on January 3, 2023.
On December 6, 2021, Dr. Jon Faiz Kayyem was appointed to the Board of Directors of Biodesix, Inc. (the “Company”), effective December 6, 2021.
Max materiality 0.85 · Median 0.65 · Most common event earnings